Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab

We described three severe asthmatics whose asthma symptoms were rapidly improved by benralizumab following favorable response to mepolizumab. Benralizumab-induced eosinophil depletion contributed to clinical improvement of severe asthma after mepolizumab-induced eosinophil reduction; thus, prior fav...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuno, Osamu, Minamoto, Seijiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6630060/
https://www.ncbi.nlm.nih.gov/pubmed/31341763
http://dx.doi.org/10.1016/j.rmcr.2019.100899
_version_ 1783435219905282048
author Matsuno, Osamu
Minamoto, Seijiro
author_facet Matsuno, Osamu
Minamoto, Seijiro
author_sort Matsuno, Osamu
collection PubMed
description We described three severe asthmatics whose asthma symptoms were rapidly improved by benralizumab following favorable response to mepolizumab. Benralizumab-induced eosinophil depletion contributed to clinical improvement of severe asthma after mepolizumab-induced eosinophil reduction; thus, prior favorable responses to mepolizumab may predict benralizumab efficacy.
format Online
Article
Text
id pubmed-6630060
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-66300602019-07-24 Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab Matsuno, Osamu Minamoto, Seijiro Respir Med Case Rep Case Report We described three severe asthmatics whose asthma symptoms were rapidly improved by benralizumab following favorable response to mepolizumab. Benralizumab-induced eosinophil depletion contributed to clinical improvement of severe asthma after mepolizumab-induced eosinophil reduction; thus, prior favorable responses to mepolizumab may predict benralizumab efficacy. Elsevier 2019-07-09 /pmc/articles/PMC6630060/ /pubmed/31341763 http://dx.doi.org/10.1016/j.rmcr.2019.100899 Text en © 2019 The Authors. Published by Elsevier Ltd. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Matsuno, Osamu
Minamoto, Seijiro
Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab
title Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab
title_full Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab
title_fullStr Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab
title_full_unstemmed Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab
title_short Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab
title_sort eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6630060/
https://www.ncbi.nlm.nih.gov/pubmed/31341763
http://dx.doi.org/10.1016/j.rmcr.2019.100899
work_keys_str_mv AT matsunoosamu eosinophilsdepletiontherapyforsevereasthmamanagementfollowingfavorableresponsetomepolizumab
AT minamotoseijiro eosinophilsdepletiontherapyforsevereasthmamanagementfollowingfavorableresponsetomepolizumab

Ejemplares similares